Bone morphogenetic protein-2 (BMP-2), a member of the transforming growth factor β (TGFβ) family, regulates osteoblast differentiation and bone formation. Here we show a novel function of BMP-2 in human osteoblasts and identify a signaling pathway involved in this function. BMP-2 promotes apoptosis in primary human calvaria osteoblasts and in immortalized human neonatal calvaria (IHNC) osteoblasts, as shown by terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) analysis. In contrast, TGFβ2 inhibits apoptosis in human osteoblasts. Studies of the mechanisms of action showed that BMP-2 increases Bax/Bcl-2 ratio whereas TGβ-2 has a negative effect. Moreover, BMP-2 increases the release of mitochondrial cytochrome c to the cytosol. Consistent with these results, BMP-2 increases caspase-9 and caspase-3, -6, -7 activity, and an anticaspase-9 agent suppresses BMP-2-induced apoptosis. Overexpression of dominant-negative Smad1 effectively blocks BMP-2-induced expression of the osteoblast transcription factor Runx2, but not the activation of caspases or apoptosis induced by BMP-2, indicating that Smad1 signaling pathway is not involved in the BMP-2-induced apoptosis. The pro-apoptotic effect of BMP-2 is PKC-dependent because BMP-2 increases PKC activity, and the selective PKC inhibitor calphostin C blocks the BMP-2-induced increased Bax/Bcl-2, caspase activity and apoptosis. In contrast, the PKA inhibitor H89, the p38 MAP kinase inhibitor SB203580 or the MEK inhibitor PD-98059 have no effect. The results show that BMP-2 uses a Smadindependent, PKC-dependent pathway to promote apoptosis via a Bax/Bcl-2 and cytochrome c-caspase-9-caspase-3, -6, 7 cascade in human osteoblasts.
SUMMARY
Bone morphogenetic protein-2 (BMP-2), a member of the transforming growth factor β (TGFβ) family, regulates osteoblast differentiation and bone formation. Here we show a novel function of BMP-2 in human osteoblasts and identify a signaling pathway involved in this function. BMP-2 promotes apoptosis in primary human calvaria osteoblasts and in immortalized human neonatal calvaria (IHNC) osteoblasts, as shown by terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) analysis. In contrast, TGFβ2 inhibits apoptosis in human osteoblasts. Studies of the mechanisms of action showed that BMP-2 increases Bax/Bcl-2 ratio whereas TGβ-2 has a negative effect. Moreover, BMP-2 increases the release of mitochondrial cytochrome c to the cytosol. Consistent with these results, BMP-2 increases caspase-9 and caspase-3, -6, -7 activity, and an anticaspase-9 agent suppresses BMP-2-induced apoptosis. Overexpression of dominant-negative Smad1 effectively blocks BMP-2-induced expression of the osteoblast transcription factor Runx2, but not the activation of caspases or apoptosis induced by BMP-2, indicating that Smad1 signaling pathway is not involved in the BMP-2-induced apoptosis. The pro-apoptotic effect of BMP-2 is PKC-dependent because BMP-2 increases PKC activity, and the selective PKC inhibitor calphostin C blocks the BMP-2-induced increased Bax/Bcl-2, caspase activity and apoptosis. In contrast, the PKA inhibitor H89, the p38 MAP kinase inhibitor SB203580 or the MEK inhibitor PD-98059 have no effect. The results show that BMP-2 uses a Smadindependent, PKC-dependent pathway to promote apoptosis via a Bax/Bcl-2 and cytochrome c-caspase-9-caspase-3, -6, 7 cascade in human osteoblasts.
INTRODUCTION
Bone formation is a complex process that involves the recruitment and proliferation of osteoprogenitor cells and their differentiation into osteoblasts (1) (2) (3) .
At the end of the formation period, osteoblasts die by apoptosis, or programmed cell death, recognized by chromatin condensation, nuclear fragmentation, DNA degradation, and formation of membrane blebbing (4) . Recent observations indicate that apoptosis has a major impact on skeletal development and remodeling.
Apoptosis is essential for the elimination of osteoblasts during skeletal development (5) (6) (7) (8) (9) . Moreover, the frequency of osteoblast apoptosis controls osteoblast lifespan and bone formation during the postnatal life (10) . Osteotropic hormones that regulate osteoblastic cell proliferation and differentiation were found to control osteoblast apoptosis (10, 11) . Some local regulatory cytokines are also known to modulate apoptosis in osteoblasts. Among them, tumor necrosis factor-α, interleukin-1 and interleukin-6, insulin-like growth factor-1 and fibroblast growth factor signaling induce pro-or anti-apoptotic effects on osteoblasts (12) (13) (14) (15) (16) , indicating an important role for local regulatory factors in the control of osteoblast apoptosis.
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β (TGFβ) family that play essential roles in osteogenesis (17) (18) (19) .
BMPs play pivotal role in the commitment and differentiation of cells of the osteoblastic lineage (20, 21) . BMP-2, a prototype of BMPs, promotes osteoblast maturation by increasing the expression of the transcription factor Runx2, previously referred to as Cbfa1/PebpαA/AML3, and the expression of osteoblast marker genes (22) (23) (24) (25) . In non skeletal cell types, BMPs were found to regulate apoptosis, although both pro-and anti-apoptotic effects have been reported (26) (27) (28) (29) (30) (31) (32) (33) . Members of the msx family or the cyclin-dependent kinase inhibitor p21 have been implicated in the pro-apoptotic activity of BMPs (26, 29, 31) . However, the signaling pathways by which BMPs induce the death program remain largely unknown (34) . Moreover, no evidence exists to suggest that BMPs have an induction role of apoptosis in osteoblasts.
BMPs signal through type I and II serine/threonine kinase receptors that phosphorylate the downstream target proteins Smads. Activation of type I BMPreceptor phosphorylates Smad1, Smad5 and presumably Smad8, and associate with Smad4 in a heteromeric complex that is translocated to the nucleus where it activates transcription (35) . TGFβ binding to receptors leads to phosphorylated Smad2 and Smad3 which associate with Smad4 and the complex can translocate to the nucleus to regulate transcriptional activity (36) (37) (38) . The Smad signaling pathway has been shown to play a role in BMP-2-induced osteoblast differentiation (39, 40) . However, other signaling pathways, such as extracellular signal-regulated kinase (ERK1/2), protein kinase C and cAMP-dependent protein kinase A (PKA) (41-43) may also be involved in the BMP-induced effects on bone cells. Another cascade is activated by TGFβ and BMP-4 and involves TAK1 (TGFβ-activated kinase-1), a member of mitogen-activated protein kinase (MAPK) kinase, p38 and c-Jun N-terminal kinase (JNK) (44, 45) . TAK-1-p38 kinase pathway was recently found to be involved in BMP-2-induced apoptosis (44, 46) . However, the molecular events underlying the effect of BMP-2 on apoptotic pathways in bone cells are not known.
We have recently shown that BMP-2 has the capacity to induce osteoblast differentiation marker genes in primary human calvaria osteoblasts as well as in immortalized human neonatal calvaria (IHNC) osteoblastic cells (25, 47) . In the present study, we have determined the effect of BMP-2 on apoptosis and investigated the signaling pathway that mediates the control of apoptosis by BMP-2 in human osteoblasts. We show here that BMP-2 promotes cell death signaling pathway, whereas TGFβ2 inhibits apoptosis in human osteoblasts. Further experiments utilizing a dominant-negative (DN)-Smad1 vector showed that the apoptotic signal induced by BMP-2 in IHNC cells is independent of the Smad1 pathway. We also provide evidence that the BMP-2-induced-apoptosis in human osteoblasts is mediated by activation of PKC, leading to activation of caspase-9, effector caspases and DNA fragmentation.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatments-Establisment and characterization of primary human calvaria cells and IHNC cells have been previously described in details (25, 47) . Both primary human calvaria cells and IHNC cells express similar osteoblast phenotypic characteristics (alkaline phosphatase, type 1 collagen, the osteoblast transcription factor Runx2 and osteocalcin) (25, 47) . Primary human calvaria cells and IHNC cells were cultured in DMEM supplemented with glutamin (292 mg/L), 10% heat inactivated Fetal Calf Sserum (FCS) and antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin). Previous studies showed that recombinant human (rh)RHBMP-2 (kindly provided by Genetics Institute, Cambridge, MA) induces a dose-dependent stimulatory effect on alkaline phosphatase (ALP) activity, an early osteoblast marker, with a maximal stimulatory effect at 50 ng/ml in these cells (25, 47) . Subsequent studies were therefore performed at this optimal dose. To analyse the effect of serum withdrawal on cell proliferation and survival, IHNC cells were cultured for 24 h in the presence of 10 % FCS or in serum-free conditions, then treated with rhBMP-2 or rhTGFβ2 for 24 h before detection of apoptosis. The cells cannot be cultured longer than 72 h in serum-deprived conditions because they detach from the substrate. (Fig. 1A) . In contrast to the effect of rhBMP-2, treatment with rhTGFβ2 (10 ng/ml) decreased by 2-fold the number of TUNELpositive primary human calvaria osteoblasts ( Fig. 1A and 1C ). In the IHNC cell line, the basal number of apoptotic cells was higher than in primary human calvaria cells, as expected from this immortalized cell line ( Fig. 1 B and 1C) . In these cells, BMP-2 also had a pro-apoptotic effect. rhBMP-2 increased the number of TUNEL-positive IHNC cells, and rhTGFβ2 reduced the number of apoptotic cells, confirming the effect of these factors documented in primary human calvaria osteoblasts ( Fig. 1B and 1C). To know if BMP-2-induced apoptosis was associated with decreased cell viability, we examined the effect of rhBMP-2 using trypan blue staining. We found that rhBMP-2 (50 ng/ml, 24 h) increased by 42 % the number of unviable trypan blue stained IHNC cells (controls: 15 ± 0.6 (sem) % vs +rhBMP-2: 21.3 ± 1.6 %, p<0.05). In contrast, rhTGF-β2 (10 ng/ml, 24 h) decreased the number of trypan blue stained IHNC cells (+rhTGF-β2: 12.5 ± 0.8 % vs controls: 15 ± 0.6 %, p<0.05).
Plasmids and Transfection-
Additional experiments using ethidium bromide/acridine orange staining indicated that BMP-2 induced apoptosis, but not necrosis (not shown).
To determine the influence of serum withdrawal on the effect of BMP-2 on increased Bax protein levels by 66 %. In contrast, rhTGβ2 had no effect ( Fig. 2A) .
Additionally, rhBMP-2 markedly decreased Bcl-2 levels, which led to increase the Bax/Bcl-2 ratio by 600 % (Fig. 2B) . Another signaling pathway leading to apoptosis involves the release of cytochrome c into cytoplasm (50) . The released cytochrome c cooperates with molecules such as Apaf-1 to activate caspase-9 and thereby caspase-3 (55, 56) . To determine if BMP-2-induced apoptosis in osteoblasts involves cytochrome c, the amounts of cytochrome c in mitochondria and cytosol were determined by Western blot analysis. As shown in Fig. 2C , the BMP-2-induced apoptosis was associated with decreased mitochondrial cytochrome c content and increased cytochrome c release in the cytosol. Cox-4, a mitochondrial marker used as control of purity of the biological samples, was not found in the cytoplasm but was present in the mitochondrial extracts, validating the purity of the preparation.
This indicates that the induction of apoptosis by BMP-2 in human osteoblasts is associated with mitochondrial release of cytochrome c.
Changes in Bax and Bcl-2 are known to balance apoptotic signals through activation of caspases (57, 58) . We thus investigated the implication of initiator caspases and effector caspases in BMP-2-induced apoptosis. Biochemical analyses showed that treatment with rhBMP-2 increased caspase-9 activity in IHNC cells, consistent with the release of cytochrome c in the cytosol (Fig. 3A) . Furthermore, rhBMP-2 increased effector caspase-3,-6,-7 activity. This effect was dosedependent in a range of 10-100 ng/ml (not shown) with a maximal effect at 50 ng/ml (Fig. 3B) . In contrast, rhTGFβ2 decreased effector caspase-3,-6,-7 activity (Fig. 3B) , consistent with its inhibitory effect on apoptosis (Fig. 1A-C) . To confirm the implication of caspases in the pro-apoptotic effect of BMP-2, IHNC cells were treated with rhBMP-2 in the presence of specific caspase inhibitors. As shown in Fig.   3C , the stimulatory effect of rhBMP-2 on the number of apoptotic cells was suppressed by the anti-caspase-9 z-LEHD-FMK, confirming the implication of caspase-9 activation in BMP-2-induced apoptosis. In contrast, the anti-caspase-8 agent (z-IETD-FMK) had no effect on rhBMP-2-induced apoptosis (Fig. 3D ).
Caspase-9 is known to promote effector caspases leading to apoptosis (59) .
Accordingly, treatment with the broad anti-effector caspase-3, -6, -7 z-DEVD-FMK compound suppressed the stimulatory effect of rhBMP-2 on apoptosis (not shown). These data indicate that osteoblast apoptosis induced by BMP-2 involves activation of caspase-9, but not caspase-8, and subsequent activation of effector caspase-3, -6, -7 in human osteoblasts. (Fig. 6B) . Likewise, PD-98059 which inhibits MEK, a kinase which lies upstream of Erk, did not suppress apoptosis induced by BMP-2. The PKA inhibitor H89 also had no effect on BMP-2-induced apoptosis (Fig. 6 B) . These data suggest that PKC, but not PKA, p38 MAPK or MEK, is involved in the apoptosis induced by BMP-2 in osteoblastic cells.
Forced Expression of Dominant Negative-Smad1 Suppresses BMP-2-induced Runx2, but not BMP-2-Induced Apoptosis in IHNC Cells

Essential Role of PKC in BMP-2-induced Apoptotic Mechanisms in IHNC
Cells-We then examined whether treatment of IHNC cells with BMP-2 leads to direct activation of PKC. Fig. 7 shows that treatment of IHNC cells with rhBMP-2 significantly enhanced the protein kinase activity of PKC at 5 and 10 min. In contrast, rhTGFβ2 had no effect on PKC activity. These result indicates that BMP-2 transiently activates the PKC pathway in IHNC cells. In order to further confirm the role of PKC in BMP-2-induced apoptosis in osteoblasts, we examined the effect of selective PKC inhibitors on the mechanisms involved in the pro-apoptotic effect of BMP-2. Western blot analysis confirmed that rhBMP-2 increased Bax/Bcl-2 ratio in IHNC cells. The amplitude of increase differed from our previous results (Fig. 2) due to the distinct solvents (DMSO vs DMEM) used in the two types of experiments. We found that, in the presence of the PKC inibitor calphostin C, the promoting effect of rhBMP-2 on Bax protein level was suppressed (Fig. 8A) . Furthermore, the rhBMP-2-induced inhibitory effect on Bcl-2 level was abolished by calphostin C (Fig. 8A) .
As a result, the promoting effect of rhBMP-2 on the Bax/Bcl-2 ratio was blocked by calphostin C (Fig. 8A) . To further document the implication of PKC in the BMP-2-induced apoptosis, we determined the effect of PKC inhibitors on the activity of caspase-9 and downstream effector caspases-3, -6, -7. As shown in Fig. 8B , pretreatment with calphostin C completely blocked the induction of caspase-9 activity by rhBMP-2. Moreover, calphostin C reduced the basal caspase-3, -6, -7 activity and abolished the effector caspase activity promoted by rhBMP-2 (Fig. 8C) .
These results indicate that PKC plays an essential role in the pro-apoptotic effect of BMP-2 in IHNC cells.
DISCUSSION
BMPs are multifunctional proteins that play essential role in the control of osteoblast differentiation. We show in this report a novel function of BMP-2 in osteoblasts: BMP-2 induces molecular events leading to apoptosis in human osteoblasts, an effect that is mediated by activation of PKC. We first demonstrated that BMP-2 increases the number of apoptotic cells in primary human calvaria osteoblasts as well as in immortalized human calvaria osteoblasts, and that this effect is independent of serum growth factors and cell growth. The pro-apoptotic effect of BMP-2 clearly differs from that of TGFβ2 which has anti-apoptotic effect, suggesting distinct regulatory role of these members of the TGFβ superfamily on human osteoblast survival. This is consistent with our previous finding showing that BMP-2 and TGFβ have antagonistic effects on cell proliferation and osteoblast marker gene expression in human osteoblasts (70) . Although BMP-2 was previously found to exert pro-and anti-apoptotic effects in other cell types (28, 32) , our data are the first to show that BMP-2 is involved in the control of apoptosis in human osteoblasts.
Apoptosis is a multiple step process implicating upstream induction phases and downstream execution stages (71) (72) (73) (74) . We studied the nature of the pathways involved in the BMP-2-induced-apoptosis in IHNC cells. One upstream pathway that plays a central role in controling cell death involves the apoptotic promoter Bax and the inhibitory protein Bcl-2. The heterodimerization of these molecules leads to balance apoptotic signals through activation of caspases (57, 58) . Our finding that BMP-2 promotes Bax and decreases Bcl-2 protein levels suggests that the proapoptotic effect of BMP-2 involves these regulatory proteins. This is supported by our finding that BMP-2 increases caspase-9 activity, which is a downstream enzyme through PKC activation. This is the first demonstration that PKC is involved in BMP-2-induced apoptosis in bone cells. Activation of PKC has been previously observed to contribute to apoptotic signaling (76) . However, the effect is dependent on the PKC isoforms involved. Novel PKC isoforms appear to be pro-apoptotic whereas classical and atypical PKC isoenzymes are associated with cell survival in a number of cell types (76) . Several PKC isoforms have been identified in osteoblasts (77) . We recently showed that PKCα/β1 isoforms are expressed in IHNC cells (78) .
Although the target PKC isoenzyme for the pro-apoptotic action of BMP-2 remains to be determined, PKC is clearly important for activation of mechanisms leading to apoptosis in human osteoblasts.
Another pathway involving TAK1-p38 MAP kinase cascade has been shown to be involved in apoptosis induced by BMP-2 in other cells (45, 46) . Because we have not examined whether BMP-2 could activate TAK1 in IHNC cells, we cannot completely exclude the possibility that TAK1-p38 signaling pathway may be involved in the BMP-2-induced apoptosis in IHNC cells. However, we found that SB203580, a specific inhibitor of p38 MAP kinase, had no effect on BMP-2-induced apoptosis. Moreover, the BMP-2-induced apoptosis was completely blocked by the PKC inhibitor, suggesting that the TAK1-p38 signal cascade is not essential for BMP-2-induced apoptotic signal in IHNC cells. Taken together, our findings indicate that p38, PKA and Smad pathways do not appear to be involved in BMP-2-induced apoptosis in IHNC cells, and suggest that this regulation appears to be mediated by a single pathway.
In summary, we demonstrate that BMP-2 is a molecular mediator of apoptosis in osteoblasts. We also show that the BMP-2-induced apoptosis is Smad- 
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